TransMedics Group, Inc. (NASDAQ:TMDX) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of TransMedics Group, Inc. (NASDAQ:TMDX) have earned a consensus recommendation of “Moderate Buy” from the ten ratings firms that are covering the stock, MarketBeat Ratings reports. Four equities research analysts have rated the stock with a hold rating and six have issued a buy rating on the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $125.40.

TMDX has been the subject of several analyst reports. Oppenheimer raised their price target on shares of TransMedics Group from $130.00 to $150.00 and gave the company an “outperform” rating in a research note on Tuesday, June 17th. Evercore ISI assumed coverage on shares of TransMedics Group in a research note on Tuesday, September 16th. They set an “outperform” rating and a $155.00 target price for the company. Morgan Stanley lifted their target price on shares of TransMedics Group from $115.00 to $123.00 and gave the stock an “equal weight” rating in a research note on Friday, August 1st. Canaccord Genuity Group lifted their target price on shares of TransMedics Group from $129.00 to $142.00 and gave the stock a “buy” rating in a research note on Tuesday, July 15th. Finally, Piper Sandler reissued an “overweight” rating and set a $145.00 target price (up previously from $125.00) on shares of TransMedics Group in a research note on Wednesday, June 4th.

TransMedics Group Price Performance

TMDX stock opened at $117.43 on Thursday. The company has a fifty day moving average price of $116.15 and a 200-day moving average price of $108.06. The company has a market capitalization of $4.00 billion, a P/E ratio of 60.84 and a beta of 2.18. TransMedics Group has a 52-week low of $55.00 and a 52-week high of $160.80. The company has a debt-to-equity ratio of 1.61, a quick ratio of 9.17 and a current ratio of 9.86.

TransMedics Group (NASDAQ:TMDX) last released its quarterly earnings results on Wednesday, July 30th. The company reported $0.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.48 by $0.44. The firm had revenue of $157.37 million during the quarter, compared to the consensus estimate of $146.64 million. TransMedics Group had a net margin of 13.49% and a return on equity of 28.02%. The company’s revenue for the quarter was up 37.7% on a year-over-year basis. During the same quarter last year, the firm earned $0.35 earnings per share. TransMedics Group has set its FY 2025 guidance at EPS. As a group, equities analysts expect that TransMedics Group will post 1 EPS for the current year.

Hedge Funds Weigh In On TransMedics Group

A number of hedge funds have recently bought and sold shares of TMDX. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in TransMedics Group by 244.7% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 3,113,082 shares of the company’s stock worth $209,448,000 after buying an additional 2,209,996 shares during the last quarter. Marshall Wace LLP grew its holdings in TransMedics Group by 258.7% in the second quarter. Marshall Wace LLP now owns 546,787 shares of the company’s stock worth $73,275,000 after purchasing an additional 394,340 shares during the period. Capital Fund Management S.A. grew its holdings in TransMedics Group by 100.4% in the first quarter. Capital Fund Management S.A. now owns 252,294 shares of the company’s stock worth $16,974,000 after purchasing an additional 126,414 shares during the period. Zevenbergen Capital Investments LLC acquired a new stake in TransMedics Group in the second quarter worth $16,286,000. Finally, Next Century Growth Investors LLC acquired a new stake in TransMedics Group in the second quarter worth $16,049,000. Institutional investors own 99.67% of the company’s stock.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.